

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Cinderella BLANCHAT et al.) Group Art Unit: 1623
)
Serial No:	10/016,706) Examiner: Krishnan Ganapathy
)
Filed:	December 11, 2001) Attorney Docket No: 7594-84862
) (SGcsbF12282/US/PCT)
)
For:	BIOMATERIAL BASED ON AN) Confirmation No. 4431
	INSOLUBILISED DEXTRAN)
	DERIVATIVE AND A GROWTH)
	FACTOR)

TERMINAL DISCLAIMER

Address to
Mail Stop: Amendment-Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your petitioner and assignee, Biodex, a company located in France represents that it is the owner of the entire interest in the above-identified U.S. Patent Application Serial No. 10/016,706 filed December 11, 2001, for Biomaterial Based On An Insolubised Dextran Derivative And A Growth Factor, as well as U.S. Patent No. 6,646,120 issued November 11, 2003, application no. 36711 September 26, 2000 filed July 23, 1999 for Dextran Derivatives, Preparation and Medicinal Applications.

The owner Biodex of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer of the conflicting U.S. Patent No. 6,646,120. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that any patent granted on the above-identified instant application and conflicting U.S. Patent No. 6,646,120

are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the conflicting patent, as shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned certifies that he is the attorney of record and that the authority to sign this Terminal Disclaimer has been delegated to him by the petitioner, assignee, and owner Biodex.

A statutory disclaimer fee of \$65 is enclosed. Authorization is hereby given to charge any deficiency in fees or any other fees in connection with the subject application to our Deposit Account No. 23-0920.

Respectfully submitted,

January 6, 2005



Thomas W. Tolpin
Registration Number 27,600
Attorney for Applicants and Assignee

Address:

Welsh & Katz, Ltd.
22nd Floor
120 South Riverside Plaza
Chicago, IL 60606

Phone: (312) 655-1500